Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Werewolf Therapeutics (HOWL) Net Income towards Common Stockholders (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Net Income towards Common Stockholders for 5 consecutive years, with -$10.2 million as the latest value for Q4 2025.

  • Quarterly Net Income towards Common Stockholders rose 49.66% to -$10.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$62.8 million through Dec 2025, up 12.2% year-over-year, with the annual reading at -$62.8 million for FY2025, 12.2% up from the prior year.
  • Net Income towards Common Stockholders for Q4 2025 was -$10.2 million at Werewolf Therapeutics, up from -$16.4 million in the prior quarter.
  • The five-year high for Net Income towards Common Stockholders was -$5.1 million in Q2 2023, with the low at -$102.5 million in Q1 2021.
  • Average Net Income towards Common Stockholders over 5 years is -$21.3 million, with a median of -$15.8 million recorded in 2022.
  • The sharpest move saw Net Income towards Common Stockholders skyrocketed 85.02% in 2022, then plummeted 260.91% in 2024.
  • Over 5 years, Net Income towards Common Stockholders stood at -$17.9 million in 2021, then soared by 33.24% to -$11.9 million in 2022, then dropped by 0.56% to -$12.0 million in 2023, then tumbled by 69.26% to -$20.3 million in 2024, then soared by 49.66% to -$10.2 million in 2025.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods came in at -$10.2 million, -$16.4 million, and -$18.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.